» Authors » Sebastio Perrini

Sebastio Perrini

Explore the profile of Sebastio Perrini including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 64
Citations 2066
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Molfetta S, Di Gioia L, Caruso I, Cignarelli A, Green S, Natale P, et al.
Diabetes Metab Res Rev . 2024 Sep; 40(6):e3842. PMID: 39298688
Aims: To compare the efficacy and safety of different hybrid closed loop (HCL) systems in people with diabetes through a network meta-analysis. Methods: We searched MEDLINE, EMBASE, CENTRAL and PubMed...
2.
Di Gioia L, Dambrosio G, Cignarelli A, Natalicchio A, Perrini S, Laviola L, et al.
Endocrine . 2024 Sep; 86(3):930-936. PMID: 39217593
Purpose: Carney complex (CNC) is a rare, autosomal dominant syndrome, most commonly caused by PRKAR1A gene mutations and characterized by pigmented skin and mucosal changes with multiple endocrine and non-endocrine...
3.
Capoccia D, Leonetti F, Natali A, Trico D, Perrini S, Sbraccia P, et al.
Acta Diabetol . 2024 Jun; 61(10):1309-1326. PMID: 38942960
The primary cause of the pandemic scale of type 2 diabetes (T2D) is the excessive and/or abnormal accumulation of adiposity resulting from a chronic positive energy balance. Any form of...
4.
Biondi G, Marrano N, Borrelli A, Rella M, DOria R, Genchi V, et al.
Int J Mol Sci . 2024 Jan; 25(1). PMID: 38203279
Diabetes mellitus is a chronic metabolic disease, the prevalence of which is constantly increasing worldwide. It is often burdened by disabling comorbidities that reduce the quality and expectancy of life...
5.
Caruso I, Di Gioia L, Di Molfetta S, Cignarelli A, Palmer S, Natale P, et al.
EClinicalMedicine . 2023 Sep; 64:102181. PMID: 37719418
Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies-such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations, and high-dose GLP-1RA-have been listed...
6.
Garruti G, Baj J, Cignarelli A, Perrini S, Giorgino F
Front Endocrinol (Lausanne) . 2023 Jun; 14:1154561. PMID: 37274345
Current views show that an impaired balance partly explains the fat accumulation leading to obesity. Fetal malnutrition and early exposure to endocrine-disrupting compounds also contribute to obesity and impaired insulin...
7.
Marrano N, Biondi G, Borrelli A, Rella M, Zambetta T, Di Gioia L, et al.
Biomolecules . 2023 Jan; 13(1). PMID: 36671568
Type 2 diabetes (T2D) and Alzheimer's diseases (AD) represent major health issues that have reached alarming levels in the last decades. Although growing evidence demonstrates that AD is a significant...
8.
Di Molfetta S, Caruso I, Cignarelli A, Natalicchio A, Perrini S, Laviola L, et al.
Diabetes Obes Metab . 2023 Jan; 25(5):1301-1310. PMID: 36661362
Aim: To evaluate the effect on glucose control of professional continuous glucose monitoring (p-CGM)-based care as compared with standard care in the management of patients with type 1 and type...
9.
Caruso I, Marrano N, Biondi G, Genchi V, DOria R, Sorice G, et al.
Diabetes Metab Res Rev . 2023 Jan; 39(3):e3609. PMID: 36637256
Hyperglucagonemia is one of the 'ominous' eight factors underlying the pathogenesis of type 2 diabetes (T2D). Glucagon is a peptide hormone involved in maintaining glucose homoeostasis by increasing hepatic glucose...
10.
Cignarelli A, Santi D, Genchi V, Conte E, Giordano F, Di Leo S, et al.
Andrology . 2022 Dec; 11(2):234-244. PMID: 36459060
Background: The very low-calorie ketogenic diet (VLCKD) represents an opportunity to attain clinically relevant weight loss in obese patients. Functional hypogonadism represents a frequent hormonal disorder associated with obesity and...